新型单分子GLP-1和氨酸受体激活剂皮下使用:一期1b/2a随机对照研究的结果
Kirsten Dahl1, Søren Toubro2, Sohan Dey3
1Novo Nordisk, Måløv, Denmark.
Lancet (London, England)
|June 23, 2025
概括
艾米克雷丁是一种新型GLP- 1和氨酸受体激动剂,在超重或肥胖的成年人中显示出显著的体重减轻. 胃肠道副作用是常见的,但可以控制,支持进一步研究其有效性.
科学领域:
- 药理学和内分泌学
- 代谢疾病和肥胖研究
背景情况:
- 艾米克雷丁是一种针对GLP-1和氨酸受体的新型单分子激动剂.
- 这项研究研究了amycretin在治疗超重和肥胖方面的潜力.
研究的目的:
- 评估皮下氨基氨酸的安全性,耐受性,药理动力学和体重影响.
- 在36周的治疗期内评估amycretin在超重或肥胖患者中的疗效.
主要方法:
- 一个随机的,安慰剂控制的1b/ 2a期研究,参与者年龄在18-55岁之间,体重过重或肥胖 (BMI 27. 0-39. 9 kg/ m2).
- 参与者每周接受一次皮下注射amycretin或安慰剂,剂量升级至60毫克.
- 主要终点是治疗出现的不良事件;次要终点包括体重变化.
主要成果:
- 与安慰剂相比,amycretin在不同剂量和治疗持续时间内显著减轻体重 (例如,60毫克-24. 3%).
- 最常见的不良反应是胃肠道,一般为轻度至中度,过时.
- 参与者中断率很高,但中断往往与治疗出现的不良事件无关.
结论:
- 每周使用一次至60毫克的皮下氨基丁,其安全性和耐受性与其他GLP- 1和阿米林激动剂相一致.
- 尽管胃肠道事件的发生率很高,但该概况支持进一步研究amycretin的减肥效果.
- 研究结果鼓励继续研究amycretin在治疗肥胖方面的潜力.
相关概念视频
Glucagon-like Receptor Agonists
435
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
435
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
276
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
276
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K


